# GSK2983559 First Time in Human Study

> **NCT03358407** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 31 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** GSK2983559
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03358407
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-11
- **Primary completion:** 2019-02-19
- **Final completion:** 2019-02-19
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Terminated due to non clinical toxicology findings and reduced safety margins.
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03358407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03358407, "GSK2983559 First Time in Human Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03358407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*